|
Once again, business does not agree with real science or clinical outcomes. The fact of the matter is that there is not real good treatment for ALS (This include the stuff that is already out there), thus the FDA will grant approval because this is a nasty disorder. Look at the medline, and you will see that it does not improve the length of survival with any significance. Yes, this is a disorder that will probably be difficult to treat anyways. The bottomline, there is not that many patients out there (40,000 total with a life span of 3 years). Not much drugs sold. The real issue is, regeneron has a better drug. How much better??? God knows, I don't have access to that data. Yes, this drug will do better than anything out there now, but what would happen at the end of the year when regeneron comes out with their drug?? Amgen is the one marketing it. Think of the market force they have. I like to hear what you all think. Stan |
